Invasive Bladder Carcinoma — Trials

Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

179 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 95
Recruiting: 59
Ph III recruiting: 12
Growth YoY: +28.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 58.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 101–110 of 110 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06630871	A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.	not yet recruiting	Phase 2	40	Fujian Medical University Union HospitalOTHER	1	Oct 10, 2024	clinicaltrials
NCT05203913	Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC)	recruiting	Phase 2	32	Fondazione Policlinico Universitario Agostino Gemelli IRCCS